Novartis Venture Fund
260
32M
144
9.29
50
0.45
59
- Stages of investment
- Areas of investment
Summary
In 1996 was created Novartis Venture Fund, which is appeared as VC. The main department of described VC is located in the Basel. The fund was located in Europe if to be more exact in Switzerland. Novartis Venture Fund appeared to be a CVC structure as part of the corporation.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Venture Fund, startups are often financed by SV Health Investors, Apple Tree Partners, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Venture Investors, Truffle Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Astellas Venture Management, Venture Investors.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Medical Device, Life Science. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Alios BioPharma, Merus, Catalyst Biosciences The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.
The fund was created by Argeris Karabelas. The overall number of key employees were 5.
The fund is constantly included in 7-12 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Novartis Venture Fund works on 4 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. When the investment is from Novartis Venture Fund the average startup value is 10-50 millions dollars.
Investments analytics
Analytics
- Total investments
- 260
- Lead investments
- 50
- Exits
- 59
- Rounds per year
- 9.29
- Follow on index
- 0.45
- Investments by industry
- Biotechnology (232)
- Health Care (144)
- Therapeutics (106)
- Medical (76)
- Pharmaceutical (71) Show 35 more
- Investments by region
-
- United States (165)
- United Kingdom (22)
- Switzerland (31)
- China (4)
- Iceland (3) Show 15 more
- Peak activity year
- 2009
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 67M
- Group Appearance index
- 0.98
- Avg. company exit year
- 9
- Avg. multiplicator
- 4.25
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ESCAPE Bio | 14 Sep 2020 | Biotechnology, Health Care, Medical | Early Stage Venture | 73M | United States, California, South San Francisco |
| Tagworks Pharmaceuticals | 22 Jun 2023 | Biotechnology, Health Care, Medical, Pharmaceutical | Early Stage Venture | 65M | Gelderland, Nijmegen, The Netherlands |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.